After retreating from many leading biotech and emerging pharmaceutical stocks in the previous two periods, short sellers returned in early March, especially in Celgene, Medivation and Pharmacyclics.
For the second time in less than a month, the biotechnology sector got whacked when once again, chatter coming from the halls of Congress hit the sector hard. This may be a…
In a new report out from Jefferies, the analysts posted a complete list of the cheapest, on a P/E basis, of the top health care stocks to buy now. Investors concerned about…
In a new research report from Deutsche Bank, the equity strategists point that the companies that are maintaining and increasing share buybacks, plus maintaining and increasing dividends, are the stocks to buy…
The pricier the stock market gets, the more important it is for investors to keep a close eye on what they are paying for stocks. Flashy momentum stocks are great for traders,…
Biotech and emerging pharmaceutical stocks continue to be hot, but short sellers shied away from many of them in late February. Those bucking that trend include BioMarin Pharmaceutical and Medivation.
After largely shying away in the previous period, short sellers returned to many of the leading biotech and emerging pharmaceutical stocks in early February. The largest upswings happened to BioMarin Pharmaceutical and…
24/7 Wall St. has tracked the short interest in leading biotech and emerging pharmaceutical stocks. By and large, short sellers shied away from these stocks in late January.
Before the markets opened Wednesday morning, drug giant Merck & Co. reported fourth-quarter and full-year 2013 results that failed to dazzle. But shares traded higher in the premarket session.
Biogen Idec surprised investors Wednesday with weaker-than-expected guidance for 2014 earnings. Amgen beat estimates late Tuesday. Celgene and Gilead Sciences report earnings on Thursday.
Like many firms on Wall Street, the biotechnology team at UBS thinks that most of the top mega-cap and large cap biotech stocks are poised to beat earnings estimates across the board.…
ThinkstockAmgen Inc. (NASDAQ: AMGN) is the second largest biotech player, and now we have seen its fourth-quarter earnings report. Earnings came in up 30% at $1.82 per share, and revenue was up…
Jon C. Ogg Here are some of the top biotech names to buy at Cowen. They presented such an extensive list that we focused on the quality large cap names and the stocks with the…
The Cowen biotechnology team has a list of top 10 surprises that are specific to the very hot biotechnology sector.
ThinkstockInvestors love dividends, particularly safe and dependable dividends that rise through time. The S&P 500 Index currently has the most companies paying dividends in nearly two decades. The year 2013 has seen…
